Sign in to fuzzto save your conversations, follow your research and come back anytime.
Piramal Pharma
SectorHealthcare
Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics (CHG) business, and an India Consumer Healthcare (ICH) business. Piramal Pharma Solutions provides integrated drug discovery, development, and manufacturing services. The company has a joint venture with Allergan in ophthalmology and a minority investment in Yapan Bio for biologics and vaccines. It is a leading player in India's self-care space with established brands. The company specializes in niche areas such as highly potent APIs, antibody drug conjugates, and biologics. In 2022, Piramal Pharma Limited was listed on the BSE and NSE following a demerger from Piramal Enterprises Limited.
In the news
Piramal Pharma cuts Chinese raw material exposure, opens $85M US lab
Piramal Pharma shares fall 3% after USFDA issues 7 UK facility observations
Cohance Lifesciences Invests $18M in ADC Strategy Expansion
Five stocks recommended for August 28: Piramal Pharma, Wockhardt
Company insights, generated from the most recent coverage.
Technicals back the up-move: Supertrend bullish, RSI at 62.5 (not yet overbought), MACD histogram positive and MFI at 67 showing money inflow.
StochRSI at 75.9 is elevated — leaves room for a short-term pullback even while the broader trend stays bullish.
NSE sustainability rating improved to 65 for FY26 and independent ESG score of 67.1 puts it in the 'Leader' band — supports eligibility for ESG-focused institutional flows.